Literature DB >> 16242220

DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy.

Nicholas J Kennedy1, Terry W Spithill, Jan Tennent, Paul R Wood, David Piedrafita.   

Abstract

DNA vaccines have proven to be an efficient means of inducing immune responses in small laboratory animals; however, their efficacy in large out-bred animal models has been much less promising. In addressing this issue, we have investigated the ability of ovine cytotoxic lymphocyte antigen 4 (CTLA-4) mediated targeting and ruminant specific CpG optimised plasmids, both alone and in combination, to enhance immune responses in sheep to the pro cathepsin B (FhCatB) antigen from Fasciola hepatica. In this study, CTLA-4 mediated targeting enhanced the speed and magnitude of the primary antibody response and effectively primed for a potent memory response compared to conventional DNA vaccination alone, which failed to induce a detectable immune response. While the CpG-augmentation of the CTLA-4 targeted construct did not further enhance the magnitude or isotype profile of the CTLA-4 induced antibody titres, it did result in the induction of significant antigen-specific, lymphocyte-proliferative responses that were not observed in any other treatment group, showing for the first time that significant cellular responses can be induced in sheep following DNA vaccination. In contrast, CpG-augmentation in the absence of CTLA-4 mediated targeting failed to induce a detectable immune response. This is the first study to explore the potential adjuvant effects of ruminant specific CpG motifs on DNA vaccine induced immune responses in sheep. The ability of CpG-augmented CTLA-4 mediated targeting to induce both humoral and cellular immune responses in this study suggests that this may be an effective approach for enhancing the efficacy of DNA vaccines in large out-bred animal models.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242220     DOI: 10.1016/j.vaccine.2005.08.076

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Current status of veterinary vaccines.

Authors:  Els N T Meeusen; John Walker; Andrew Peters; Paul-Pierre Pastoret; Gregers Jungersen
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

Review 2.  DNA vaccines: roles against diseases.

Authors:  Kishwar Hayat Khan
Journal:  Germs       Date:  2013-03-01

3.  Evaluation of protective effect of multi-epitope DNA vaccine encoding six antigen segments of Toxoplasma gondii in mice.

Authors:  Shan Liu; Lin Shi; Yan-bin Cheng; Gui-xiang Fan; Hui-xun Ren; Yu-kang Yuan
Journal:  Parasitol Res       Date:  2009-03-14       Impact factor: 2.289

4.  A major cathepsin B protease from the liver fluke Fasciola hepatica has atypical active site features and a potential role in the digestive tract of newly excysted juvenile parasites.

Authors:  Simone A Beckham; David Piedrafita; Carolyn I Phillips; Nirma Samarawickrema; Ruby H P Law; Peter M Smooker; Noelene S Quinsey; James A Irving; Deanne Greenwood; Steven H L Verhelst; Matthew Bogyo; Boris Turk; Theresa H Coetzer; Lakshmi C Wijeyewickrema; Terry W Spithill; Robert N Pike
Journal:  Int J Biochem Cell Biol       Date:  2009-02-20       Impact factor: 5.085

5.  Evaluation of the immune responses induced by four targeted DNA vaccines encoding the juvenile liver fluke antigen, cathepsin B in a mouse model.

Authors:  Rama Jayaraj; David Piedrafita; Terry Spithill; Peter Smooker
Journal:  Genet Vaccines Ther       Date:  2012-08-31

6.  Fusion with extracellular domain of cytotoxic T-lymphocyte-associated-antigen 4 leads to enhancement of immunogenicity of Hantaan virus DNA vaccines in C57BL/6 mice.

Authors:  Feng Liu; Mifang Liang; Shouchun Cao; Qinzhi Liu; Quanfu Zhang; Chuan Li; Shuo Zhang; Shiwen Wang; Dexin Li
Journal:  Virol J       Date:  2011-09-23       Impact factor: 4.099

Review 7.  Emerging Concepts and Technologies in Vaccine Development.

Authors:  Morgan Brisse; Sophia M Vrba; Natalie Kirk; Yuying Liang; Hinh Ly
Journal:  Front Immunol       Date:  2020-09-30       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.